Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.38 |
| ▸ | PTAFR | P25105 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | FTH1 | P02794 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979494 | 0.76 | HSD11B1 (0.35) | CYP3A4PTAFRALDH1A1 | |
| SCHEMBL4442384 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL8478854 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL1171547 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL8478851 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL23295977 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL1649604 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL20721720 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL22769642 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL5935443 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124654-B2 | Derivatives of hypoestoxide and related compounds | IMMUNE MODULATION, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124654-B2 | Derivatives of hypoestoxide and related compounds | IMMUNE MODULATION, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | IMMUNE MODULATION, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | IMMUNE MODULATION, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | CYP8B1, HAAO, CYP27A1 | CYP3A4 296/4885PTAFR 983/4885ALDH1A1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.